Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3 results about "Diffuse large B-cell lymphoma" patented technology

Diffuse large B-cell lymphoma is a cancer of B cells, a type of white blood cell responsible for producing antibodies. It is the most common type of non-Hodgkin lymphoma among adults, with an annual incidence of 7–8 cases per 100,000 people per year in the USA and the UK. This cancer occurs primarily in older individuals, with a median age of diagnosis at approximately 70 years of age, though it can also occur in children and young adults in rare cases. DLBCL is an aggressive tumor which can arise in virtually any part of the body, and the first sign of this illness is typically the observation of a rapidly growing mass, sometimes associated with B symptoms—fever, weight loss, and night sweats.

Method for screening B-cell lymphoma biomarkers

PendingCN122050535Aimproved prognosisImprove enrichmentBiostatisticsBiological modelsOncologyCell subpopulations
The invention discloses a method for screening a B-cell lymphoma biomarker, and belongs to the technical field of bioinformatics. The invention aims to provide a more accurate and simple method for screening the B-cell lymphoma biomarker. The invention provides a method for screening a B cell lymphoma biomarker. The relation between the infiltration ratio of all cell subgroups of T / NK and myeloid cells and the lifetime of a patient is screened out by utilizing scRNA-seq data of Burki lymphoma, diffuse large B cell lymphoma, follicular lymphoma and spleen marginal region lymphoma and bulk RNA-seq data of a Burki lymphoma and diffuse large B cell lymphoma database. And a theoretical basis is provided for screening survival analysis of lymphoma diseases.
Owner:CHONGQING MEDICAL UNIVERSITY

Tumor microenvironment-based methods for assessing CAR-T and other immunotherapies

ActiveUS12580049B2Microbiological testing/measurementBiostatisticsAntigen receptorsDiffuse large cell lymphoma
Aspects of the disclosure relate to methods for determining whether or a subject is likely to respond to certain adoptive cell therapies (e.g., chimeric antigen receptor (CAR) T-cell therapy, etc.). In some embodiments, the methods comprise the steps of identifying a subject as having a tumor microenvironment (TME) type based upon a molecular-functional (MF) expression signature of the subject, and determining whether or not the subject is likely to respond to a chimeric antigen receptor (CAR) T-cell therapy based upon the TME type. In some embodiments, the methods comprise determining the lymphoma microenvironment (LME) type of a lymphoma (e.g., Diffuse Large B cell lymphoma (DLBCL)) subject and identifying the subjects prognosis based upon the LME type determination.
Owner:BOSTONGENE CORP

Combination therapy with Anti-CD19 / Anti-CD28 bispecific antibody

PendingUS20260184787A1Antiendomysial antibodiesCD137
The present invention relates to combination therapies employing an anti-CD20 / anti-CD3 bispecific antibody in combination with an anti-CD19 / anti-CD28 bispecific antibody and a CD19-targeted 4-1BB (CD137) agonist and the use of these combination therapies for the treatment of B-cell cancer such as diffuse large B cell lymphoma (DLBCL).
Owner:F HOFFMANN LA ROCHE INC